NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board. Mr. Epstein was CEO of Seagen before closing its sale to Pfizer in December 2023. David previously served as Executive Partner at Flagship Pioneering as well as CEO of Novartis Pharmaceuticals.

纽约，2024年2月27日/PRNewswire/--摩根大通生命科学私人资本今天宣布，其医疗保健顾问委员会将增加大卫·爱泼斯坦（DavidEpstein）。爱泼斯坦先生在2023年12月完成对辉瑞的出售之前曾担任希根的首席执行官。David之前曾担任Flagship Expediantive的执行合伙人以及诺华制药的首席执行官。

His 30 years of industry experience includes drug development, deal making, venture investing, commercialization, and leadership experience on a global scale..

他30年的行业经验包括药物开发，交易，风险投资，商业化以及全球范围的领导经验。。

Mr. Epstein will now advise the J.P. Morgan Life Sciences Private Capital team. The team invests in both early and growth-stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and Neuropsychology..

爱泼斯坦先生现在将为摩根大通生命科学私人资本团队提供咨询。该团队根据特定的市场机会，通过多种策略投资于早期和成长期的医疗保健公司，重点关注几个目标领域的新疗法和技术，包括遗传医学，肿瘤学，神经退行性疾病，罕见疾病，自身免疫，AI/ML平台，代谢疾病和神经心理学。。

'As we continue on the journey of therapeutic innovation, we are excited about our ability to bring together some of the industry's best minds with J.P. Morgan's extensive healthcare ecosystem to capture compelling investment opportunities,' said Stephen Squinto, Chief Investment Officer of J.P. Morgan Life Sciences Private Capital.

摩根大通生命科学私人资本（J.P.Morgan Life Sciences Private Capital）首席投资官斯蒂芬·斯金托（Stephen Squinto）说，随着我们继续进行治疗创新之旅，我们很高兴能够将业内一些最优秀的人才与摩根大通（J.P.Morgan）广泛的医疗保健生态系统结合起来，抓住引人注目的投资机会。

'David brings a diverse set of skills and expertise to the table and we are thrilled he has agreed to join us in our quest for innovation in life sciences.'.

“大卫为我们带来了各种各样的技能和专业知识，我们很高兴他同意加入我们对生命科学创新的追求。”。

The J.P. Morgan Life Sciences Private Capital team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a venture and growth equity investment platform that is part of J.P. Morgan Asset Management. The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, and life sciences sectors..

摩根大通生命科学私人资本团队利用摩根大通的规模、资源、数据资产和医疗保健专业知识，位于摩根大通私人资本（J.P.Morgan Private Capital）内，这是一个风险和成长股权投资平台，是摩根大通资产管理的一部分。该平台为私营公司的持续增长提供资金，并利用消费者和技术以及生命科学领域的重大IPO前价值创造机会。。

J.P. Morgan Life Sciences Private Capital has attracted a group of Strategic Advisors comprised of some of the life sciences industry's foremost experts that will help guide the investment strategy, help to source investment opportunities and provide operational expertise to J.P. Morgan's portfolio companies.

J、 摩根大通生命科学私人资本（P.Morgan Life Sciences Private Capital）吸引了一批战略顾问，他们由一些生命科学行业最顶尖的专家组成，将帮助指导投资战略，帮助寻找投资机会，并为摩根大通的投资组合公司提供运营专业知识。

With the addition of Mr. Epstein, Strategic Advisors include:.

除爱泼斯坦先生外，战略顾问包括：。

David Epstein – Past Chief Executive Officer, Seagen Inc.

David Epstein–Seagen Inc.前任首席执行官。

Laurie Glimcher, M.D. – President and CEO, Dana Farber Cancer Institute

医学博士Laurie Glimcher，Dana Farber癌症研究所总裁兼首席执行官

Jeffrey Leiden, M.D., Ph.D. – Executive Chairman, Vertex Pharmaceuticals

Jeffrey Leiden，医学博士，博士-Vertex Pharmaceuticals执行主席

Frederic Moll, M.D. – Chief Development Officer, J&J Medical Devices Companies

医学博士弗雷德里克·摩尔（FredericMoll）——强生医疗器械公司首席开发官

Stephen Oesterle, M.D. – Former Medtronic SVP, Medicine and Technology

Stephen Oesterle，医学博士-前美敦力医学与技术高级副总裁

Biographies – Strategic Advisors

传记–战略顾问

David Epstein was most recently chief executive officer of Seagen, a company that discovers, develops, manufactures, and commercializes targeted cancer therapeutics with antibody-drug conjugates at its core. During David's tenure at Seagen, its portfolio of innovative targeted cancer medicines grew significantly and he ultimately led the merger of Seagen with Pfizer. David is also a board member at Valo Health, a company using AI and machine learning technology to reimagine drug discovery and development.

DavidEpstein最近担任Seagen的首席执行官，Seagen是一家以抗体-药物偶联物为核心发现、开发、制造和商业化靶向癌症治疗药物的公司。David在Seagen任职期间，其创新靶向癌症药物的组合显着增长，他最终领导了Seagen与辉瑞的合并。David还是Valo Health的董事会成员，该公司使用人工智能和机器学习技术来重新想象药物的发现和开发。

From 2010-2016, David served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis' Oncology and Molecular Diagnostic units. David's experience also extends to early-stage discovery and innovation. He served as a consultant to Flagship Pioneering, a developer of bioplatform companies, Invus and several other firms.

2010年至2016年，David担任诺华制药公司的首席执行官。此前，David创办并领导了诺华的肿瘤学和分子诊断部门。David的经验还扩展到早期发现和创新。他曾担任旗舰创业公司（Flagship Exponential）的顾问，该公司是生物平台公司、Invus和其他几家公司的开发商。

He has served as Chairman at Rubius Therapeutics, Axcella Therapeutics, Evelo Bio and as a board member at Ring Therapeutics, Tarus Therapeutics until its successful sale in June 2022, Senti Bio, Woosley Pharma and Cellestia AG. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Gleevec, Tasigna, Gilenya, Afinitor, Cosentyx and Entresto.

他曾担任Rubius Therapeutics，Axcella Therapeutics，Evelo Bio的董事长，以及Ring Therapeutics，Tarus Therapeutics的董事会成员，直到2022年6月成功出售，Senti Bio，Woosley Pharma和Cellestia AG。在他的职业生涯中，他领导了30多个新分子实体的开发和商业化，包括Gleevec，Tasigna，Gilenya、Afinitor、Cosentyx和Entresto。

His teams gained approval for over 100 new indications and launched three Prix Galien award winning medicines. He was also recognized by FierceBiotech as one of the '25 most influential people in biopharma.'.

他的团队获得了100多种新适应症的批准，并推出了三种加利恩奖获奖药物。他还被FierceBiotech评为“生物制药领域最具影响力的25人”之一。

Laurie H. Glimcher, M.D. was named President and CEO of the Dana-Farber Cancer Institute in 2016. She is also Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University.

2016年，医学博士劳里·H·格里姆彻（LaurieH.Glimcher）被任命为达纳·法伯癌症研究所（DanaFarber Cancer Institute）总裁兼首席执行官。她还是达纳·法伯/哈佛癌症中心主任以及哈佛医学院理查德·史密斯和苏珊·史密斯医学教授。此前，她是威尔·康奈尔医学院院长兼医学教授兼康奈尔大学医学事务教务长。

Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research. She is a Member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society, Fellow of the American Academy of Arts and Sciences and the former President of the American Association of Immunologists.

格里姆彻博士是一位杰出的免疫学家，因其在癌症研究最有希望的领域之一的工作而闻名。她是美国国家科学院、国家医学院和美国哲学学会的成员，美国艺术与科学院院士，美国免疫学家协会前主席。

She previously served on the Board of Directors of Bristol-Myers Squibb Pharmaceutical Corporation, GlaxoSmithKline Pharmaceutical Corporation and the Waters Corporation.  She currently serves on the Board of Directors of Analog Devices, Inc..

她曾担任百时美施贵宝制药公司、葛兰素史克制药公司和沃特斯公司的董事会成员。她目前在Analog Devices，Inc.董事会任职。。

Jeffrey Leiden, M.D, Ph.D., is a physician and scientist who has dedicated his career to improving the lives of people with serious diseases. He currently serves as Vertex's Executive Chairman and was the Chief Executive Officer and President from 2012 through March 2020. He has been a member of Vertex's board of directors since July 2009, chairman of the board of directors since May 2012, and served as lead independent director from October 2010 through December 2011.

杰弗里·莱顿（JeffreyLeiden）是一名医生和科学家，他的职业生涯致力于改善严重疾病患者的生活。他目前担任Vertex的执行主席，从2012年到2020年3月担任首席执行官和总裁。他自2009年7月起担任Vertex董事会成员，自2012年5月起担任董事会主席，并于2010年10月至2011年12月担任首席独立董事。

Prior to joining Vertex, Dr. Leiden was a managing director at Clarus Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President, Chief Operating Officer and Chief Scientific Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the board of directors of Abbott Laboratories from 2000 to 2006.

在加入Vertex之前，莱顿博士曾于2006年至2012年1月担任生命科学风险投资公司Clarus Ventures的董事总经理。2000年至2006年，莱顿博士曾任制药产品集团雅培实验室总裁、首席运营官和首席科学官，也是雅培实验室董事会成员。

He is an elected member of both the American Academy of Arts and Sciences and the National Academy of Medicine. Dr. Leiden serves as a director of Massachusetts Mutual Life Insurance Company and as chairman of Odyssey Therapeutics, a privately held company developing novel medicines for the treatment of cancer and autoimmune diseases and Casana Health, a privately held home-health monitoring company.

他是美国艺术与科学院和国家医学院的当选成员。莱顿博士是马萨诸塞州互助人寿保险公司的董事，也是Odyssey Therapeutics（一家开发治疗癌症和自身免疫性疾病的新药的私营公司）和Casana Health（一家私营家庭健康监测公司）的董事长。

He is also chairman of the board of Revolution Healthcare (REVH), a SPAC focused on companies that utilize novel technologies to revolutionize the treatment and delivery of mental healthcare. He is also a member of the MIT CEO Advisory Board, a member of the Harvard Medical School Board of Fellows, and chairman of the Massachusetts Competitive Partnership (MACP).

他还是革命医疗委员会（REVH）主席，该委员会专注于利用新技术彻底改变精神医疗治疗和提供的公司。他还是麻省理工学院CEO顾问委员会成员、哈佛医学院院士委员会成员、马萨诸塞州竞争伙伴关系（MACP）主席。

Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago..

莱顿博士获得了芝加哥大学的医学博士、博士和学士学位。。

Frederic (Fred) Moll, M.D. is Chief Development Officer of J&J Medical Devices Companies, having sold his sixth company, Auris Health, Inc., to J&J for $5.75 billion in 2019. Fred was the co-founder and CEO of Intuitive Surgical, the world's leading medical robotics company today, with a market capitalization exceeding $100 billion.

Frederic（Fred）Moll，医学博士是强生医疗器械公司的首席开发官，2019年以57.5亿美元的价格将他的第六家公司Auris Health，Inc.出售给强生。弗雷德是当今世界领先的医疗机器人公司Intuitive Surgical的联合创始人兼首席执行官，该公司市值超过1000亿美元。

Fred is not only considered the 'Father of Robotic Surgery' (having also founded Hansen Medical), Fred conceived and commercialized the early critical products that allowed minimally invasive laparoscopic surgery to be performed safely with his invention of the safety shield trocar (Endotherapeutics) and balloon distention tools (Origin MedSystems).

弗雷德不仅被认为是“机器人手术之父”（他还创立了汉森医疗公司），弗雷德还构思并商业化了早期的关键产品，通过发明安全防护套管针（Endotherapeutics）和气囊扩张工具（Origin MedSystems），可以安全地进行微创腹腔镜手术。

Fred attended the University of California at Berkeley where he earned a B.A. degree, earned his M.D. degree from the University of Washington and attained an M.S. in Management from the Stanford Business School..

弗雷德就读于加州大学伯克利分校，在那里他获得了学士学位，在华盛顿大学获得了医学博士学位，并在斯坦福商学院获得了管理硕士学位。。

Stephen Oesterle, M.D. served as Medtronic's Senior Vice President for Medicine and Technology, was a member of the Medtronic Executive Committee for 14 years, and currently serves on four public life sciences/healthcare boards. By forging relationships with global technology partners and technical universities, he oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies.

医学博士斯蒂芬·奥斯特尔（StephenOesterle）曾担任美敦力医学与技术高级副总裁，曾任美敦力执行委员会成员14年，目前在四个公共生命科学/医疗保健委员会任职。通过与全球技术合作伙伴和技术大学建立关系，他监督了长期的内部技术投资，同时参与了新兴私营公司的战略性企业投资。

He also served as a member of the Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic Dr. Oesterle served on more than 20 boards as a director or observer and built a strong and enduring profile for Medtronic in the global venture capital and private equity communities.

他还担任批准所有公司收购的业务发展和战略委员会成员。在美敦力任职期间，Oesterle博士曾担任20多个董事会的董事或观察员，并在全球风险投资和私人股本界为美敦力建立了强大而持久的形象。

Prior to joining Medtronic, he was an associate professor at Harvard Medical School and practicing interventional cardiologist. Steve earned his bachelor's degree with Distinction at Harvard University and his MD at Yale Medical School..

在加入美敦力之前，他是哈佛医学院的副教授和执业介入心脏病专家。史蒂夫在哈佛大学以优异成绩获得学士学位，在耶鲁医学院获得医学博士学位。。

About J.P. Morgan Global Alternatives & J.P. Morgan Private Capital

关于摩根大通全球替代品和摩根大通私人资本

J.P. Morgan Private Capital provides customized financing solutions for private companies across the capital structure with a focus on venture and growth investing. The platform's solutions span the consumer, technology, and life sciences sectors. J.P. Morgan Private Capital is part of J.P. Morgan Global Alternatives, the alternative investment arm of J.P.

J、 摩根大通私人资本（P.Morgan Private Capital）在整个资本结构中为私营公司提供定制的融资解决方案，重点是风险投资和增长投资。该平台的解决方案涵盖消费者、技术和生命科学领域。J、 摩根大通私人资本是摩根大通全球替代投资公司（J.P.Morgan Global Alternatives）的一部分。

Morgan Asset Management. With more than 60 years as an alternatives investment manager, US$213 billion in assets under management and more than 800 professionals (as of December 31, 2023), J.P. Morgan offers strategies across the alternative investment spectrum including real estate, private equity, private credit, hedge funds, infrastructure, transportation, timber and liquid alternatives.

摩根资产管理公司。摩根大通拥有60多年的另类投资管理经验，管理着2130亿美元的资产，拥有800多名专业人士（截至2023年12月31日），为包括房地产、私募股权、私人信贷、对冲基金、基础设施、运输、木材和流动性另类投资在内的另类投资领域提供战略。

Operating from offices throughout the Americas, Europe and Asia Pacific, our independent alternative investment engines combine specialist knowledge and singular focus with the global reach, vast resources and powerful infrastructure of J.P. Morgan to help meet each client's specific objectives..

我们的独立替代投资引擎在美洲、欧洲和亚太地区设有办事处，将专业知识和独特的专注力与摩根大通的全球影响力、丰富的资源和强大的基础设施相结合，帮助实现每个客户的具体目标。。

About J.P. Morgan Asset Management

关于摩根大通资产管理

J.P. Morgan Asset Management, with assets under management of $3.1 trillion (as of 12/31/2023), is a global leader in investment management. J.P. Morgan Asset Management's clients include institutions, retail investors and high net worth individuals in every major market throughout the world. J.P. Morgan Asset Management offers global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity.

J、 截至2023年12月31日，摩根大通资产管理公司管理的资产为3.1万亿美元，是投资管理领域的全球领导者。J、 摩根大通资产管理公司的客户包括全球各主要市场的机构、散户投资者和高净值个人。J、 摩根大通资产管理公司提供股票、固定收益、房地产、对冲基金、私人股本和流动性方面的全球投资管理。

For more information: www.jpmorganassetmanagement.com. J.P. Morgan Asset Management is the marketing name for the asset management businesses of JPMorgan Chase & Co., and its affiliates worldwide..

更多信息：www.jpmorganassetmanagement.com。摩根大通资产管理是摩根大通及其全球附属公司资产管理业务的市场名称。。

JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America ('U.S.'), with operations worldwide. JPMorgan Chase had $3.9 trillion in assets and $328 billion in stockholders' equity as of December 31, 2023. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management.

摩根大通公司（纽约证券交易所代码：JPM）是一家总部位于美国（“美国”）的领先金融服务公司，业务遍及全球。截至2023年12月31日，摩根大通拥有3.9万亿美元资产和3280亿美元股东权益。该公司是投资银行、消费者和小企业金融服务、商业银行、金融交易处理和资产管理领域的领导者。

Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world's most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com..

在摩根大通（J.P.Morgan）和大通（Chase）品牌旗下，该公司为美国数百万客户以及全球许多最著名的企业、机构和政府客户提供服务。有关摩根大通公司的信息，请访问www.jpmorganchase.com。。

SOURCE J.P. Morgan Asset Management

来源：摩根大通资产管理